aTYR PHARMA INC
ATYR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001339970
No open-market purchases or sales by aTYR PHARMA INC insiders were filed in the last 90 days; 89 institutions reported holding it in 13F filings for Q2 2026, worth $23.2M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding aTYR PHARMA INC changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 25 | 29 | +4 |
| Shares | 5.91M | 6.92M | +1.01M (+17.1%) |
| Value | $26.3M | $33.8M | +$7.45M (+28.3%) |
New holders (7)
Institutions that held aTYR PHARMA INC at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| State Street Corp | 55,199 | $269.0K | 0.00% |
| Millennium Management LLC | 30,386 | $148.0K | 0.00% |
| Two Sigma Investments, LP | 14,446 | $70.0K | 0.00% |
| XTX Topco Ltd | 12,265 | $60.0K | 0.02% |
| Susquehanna International Group, LLP | 10,839 | $53.0K | 0.00% |
| UBS Group AG | 3,164 | $15.0K | 0.00% |
| Royal Bank of Canada | 1 | $0 | 0.00% |
Sold out (3)
Institutions that held aTYR PHARMA INC at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Spire Wealth Management | 14,000 | $63.0K |
| ExodusPoint Capital Management, LP | 11,066 | $49.0K |
| Sowell Financial Services LLC | 100 | $0 |